Careers  |  Sign In  |  Register

Latest in Oncology

Geoffrey Oxnard, MD, associate professor of medicine at Harvard Medical School, discusses the advancements in treatments for lung cancer over the past 10 to 15 years. Even though targeted therapies and immunotherapies are not effective in a large percentage of patients with advanced non-small cell lung...
Lyudmila A. Bazhenova, MD, professor of medicine at UC San Diego Health, discusses the lack of data on chemoimmunotherapy or monotherapy immunotherapy for treatment of ALK-fused non-small cell lung cancer (NSCLC). Learn more by clicking...
Results from a cohort study suggest that vision loss, a common side effect after plaque radiotherapy for uveal melanoma, may be mitigated or avoided entirely thanks to prophylactic anti-vascular endothelial growth factor treatment. By employing intravitreal bevacizumab patients had better outcomes...